This review briefly summarises pharmacological and clinical characteristics of rasagiline (AZILECT®) that are
relevant in the context of treating symptomatic treatment of idiopathic Parkinson’s disease as monotherapy
and as adjunct therapy to dopamine agonists or to levodopa.
Independent commentary has been provided by Dr. Kelly Bertram, a movement disorders neurologist, based at the Alfred Hospital, Melbourne.
Please login below to download this issue (PDF)